@entity1369 has long been known to mediate water and electrolyte balance by acting on mineralocorticoid receptors in the kidneys. However, recent studies have demonstrated the presence of these receptors in nonclassical locations, including the brain, blood vessels, and the heart. This finding suggests that @entity1369 may play a larger role than once appreciated in normal physiologic function and @entity65 . Some of the adverse cardiovascular effects that have been described include @entity299 , @entity4346 , @entity712 , @entity101 , @entity409 , reduced fibrinolysis, and @entity943 . In light of these findings, @entity1369 receptor blockers have become increasingly more important. This is especially true considering the fact that traditional therapies, such as angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, may not be effective in maintaining long-term suppression of @entity1369 . Therefore, a great deal of focus has been placed on @entity1482 , which has proven to be an effective, albeit nonselective, @entity1369 receptor blocker. The Randomized @entity1482 Evaluation Study has shown that @entity1482 results in a 30% reduction in mortality among @entity1 with severe @entity712 . Other studies have shown @entity1482 to lower high blood pressure, improve @entity409 , reduce @entity4346 , and lower the incidence of fatal @entity943 . However, @entity1482 , because of its interaction with other @entity134 receptors, is not without its limitations, which include @entity247 , breast tenderness, @entity1866 , and @entity323 . As a result, @entity14292 ( @entity14292 ), a selective @entity1369 blocker, is currently being investigated for its efficacy and side-effect profile compared with @entity1482 . @entity14292 has already been approved for the treatment of systemic @entity101 , and several clinical trials are currently underway to identify other therapeutic uses for this agent in @entity65 management.

@entity1369 and @entity1369 antagonism in XXXX : focus on @entity14292 (Inspra).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity323 :: ('MESH:D007172', 'Disease') :: ['impotence'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone', 'Aldactone'] @entity14292 :: ('MESH:C414690', 'Chemical') :: ['eplerenone', 'INSPRA', 'Eplerenone'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity247 :: ('MESH:D006177', 'Disease') :: ['gynecomastia'] @entity1866 :: ('MESH:D008599', 'Disease') :: ['menstrual irregularities'] @entity4346 :: ('MESH:D017379', 'Disease') :: ['left ventricular hypertrophy'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac and vascular fibrosis'] @entity943 :: ('MESH:D001145', 'Disease') :: ['cardiac arrhythmias', 'arrhythmias'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity65 :: (MESH:D002318,Disease) :: ['cardiovascular disease']
